AVEO Oncology, an LG Chem Company

AVEO Oncology is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. In 2023, AVEO was acquired by LG Chem, Ltd., establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in the U.S. To learn more visit FOTIVDAHCP.com.